Previous close | 28.80 |
Open | 28.80 |
Bid | 0.00 x 1200 |
Ask | 0.00 x 1100 |
Day's range | 28.80 - 32.64 |
52-week range | 13.84 - 62.49 |
Volume | |
Avg. volume | 1,550,656 |
Market cap | 1.316B |
Beta (5Y monthly) | -0.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.16 |
Earnings date | 27 Feb 2023 - 03 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 13 Dec 2012 |
1y target est | 84.00 |
On any list of biotech plays that might multiply in value in a relatively short period, Cassava Sciences (NASDAQ: SAVA) is likely to be near the top of the list. It's exploring whether its drug called simufilam is safe and effective to treat early-stage Alzheimer's disease, though its clinical trials have (so far) shed little light on the issue. The biggest reason to sell Cassava stock: After an open-label phase 2 clinical trial of simufilam, the market reacted quite negatively to the release of new data that management spun as being positive.
Figure 1 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, mild-to-moderate disease.¹ Figure 2 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, in early disease and mild disease.² ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets.47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 point
Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.